<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39362845</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage.</ArticleTitle><Pagination><StartPage>8550</StartPage><MedlinePgn>8550</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8550</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-52668-w</ELocationID><Abstract><AbstractText>The SARS-CoV-2 BA.2.86 lineage, and its sublineage JN.1 in particular, achieved widespread transmission in the US during winter 2023-24. However, this surge in infections was not accompanied by COVID-19 hospitalizations and mortality commensurate with prior waves. To understand shifts in COVID-19 epidemiology associated with JN.1 emergence, we compared characteristics and clinical outcomes of time-matched cases infected with BA.2.86 lineages (predominantly representing JN.1) versus co-circulating XBB-derived lineages in December, 2023 and January, 2024. Cases infected with BA.2.86 lineages received greater numbers of COVID-19 vaccine doses, including XBB.1.5-targeted boosters, in comparison to cases infected with XBB-derived lineages. Additionally, cases infected with BA.2.86 lineages experienced greater numbers of documented prior SARS-CoV-2 infections. Cases infected with BA.2.86 lineages also experienced lower risk of progression to severe clinical outcomes requiring emergency department consultations or hospital admission. Sensitivity analyses suggested under-ascertainment of prior infections could not explain this apparent attenuation of severity. Our findings implicate escape from immunity acquired from prior vaccination or infection in the emergence of the JN.1 lineage and suggest infections with this lineage are less likely to experience clinically-severe disease. Monitoring of immune escape and clinical severity in emerging SARS-CoV-2 variants remains a priority to inform responses.</AbstractText><CopyrightInformation>Â© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewnard</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-8505-8839</Identifier><AffiliationInfo><Affiliation>School of Public Health, University of California, Berkeley, Berkeley, CA, USA. jLewnard@berkeley.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahale</LastName><ForeName>Parag</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malden</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0567-8294</Identifier><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Vennis</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackerson</LastName><ForeName>Bradley K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-0816-7345</Identifier><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewin</LastName><ForeName>Bruno J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0003-1483-2791</Identifier><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Link-Gelles</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9617-806X</Identifier><AffiliationInfo><Affiliation>Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control &amp; Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldstein</LastName><ForeName>Leora R</ForeName><Initials>LR</Initials><Identifier Source="ORCID">0000-0002-4430-6760</Identifier><AffiliationInfo><Affiliation>COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipsitch</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tartof</LastName><ForeName>Sara Y</ForeName><Initials>SY</Initials><Identifier Source="ORCID">0000-0003-2336-8476</Identifier><AffiliationInfo><Affiliation>Department of Research &amp; Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI148336</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AI148336</GrantID><Agency>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Apr 19:2024.04.17.24305964. doi: 10.1101/2024.04.17.24305964</RefSource><PMID Version="1">38699313</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057131" MajorTopicYN="Y">Immune Evasion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>J.A.L. has received research grants paid directly to his institution and consulting honoraria unrelated to this study from Pfizer. S.Y.T. has received research grants paid directly to her institution unrelated to this study from Pfizer. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39362845</ArticleId><ArticleId IdType="pmc">PMC11450198</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-52668-w</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-52668-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>US Centers for Disease Control and Prevention. Risk assessment summary for SARS CoV-2 sublineage BA.2.86. https://www.cdc.gov/ncird/whats-new/covid-19-variant.html (2024).</Citation></Reference><Reference><Citation>US Centers for Disease Control and Prevention. CDC continues to track the growth of JN.1.https://www.cdc.gov/ncird/whats-new/JN.1-update-2023-12-22.html (2024).</Citation></Reference><Reference><Citation>Jeworowski, L. M. et al. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Eurosurveillance29, 2300740 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10785204</ArticleId><ArticleId IdType="pubmed">38214083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheward, D. J. et al. Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses. Lancet Infect. Dis.23, e462âe463 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37776877</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis.24, e70âe72 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, S. et al. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86. Lancet Infect. Dis.23, e457âe459 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37738994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature624, 639â644 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37871613</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention. Wastewater: COVID-19 national and regional trends. https://www.cdc.gov/nwss/rv/COVID19-nationaltrend.html (2024).</Citation></Reference><Reference><Citation>US Centers for Disease Control and Prevention. COVID data tracker. Available from: https://covid.cdc.gov/covid-data-tracker. Accessed 24 March, 2024.</Citation></Reference><Reference><Citation>Lewnard, J. A. et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California. Nat. Med.28, 1933â1943 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10208005</ArticleId><ArticleId IdType="pubmed">35675841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard, J. A. et al. Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome. Nat. Commun.14, 1407 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10012300</ArticleId><ArticleId IdType="pubmed">36918548</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard, J. A. et al. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant. Nat Commun14, 3854 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10310822</ArticleId><ArticleId IdType="pubmed">37386005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter, N. et al. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat. Commun.13, 5860 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531215</ArticleId><ArticleId IdType="pubmed">36195617</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature593, 270â274 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170116</ArticleId><ArticleId IdType="pubmed">33723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg, T. et al. Comparative analysis of the risks of hospitalization and death associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants in England: a cohort study. Lancet399, 1303â1312 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Koebnick, C. et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau Data. Perm. J.16, 37â41 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442759</ArticleId><ArticleId IdType="pubmed">23012597</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, A. C., Voelkel, J. L., Remmers, C. L., Adams, J. L. &amp; McGlynn, E. A. Comparing Kaiser Permanente members to the general population: implications for generalizability of research. Perm. J.27, 87â98 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10266863</ArticleId><ArticleId IdType="pubmed">37170584</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrejko, K. L. et al. Real-world uptake of COVID-19 vaccination among individuals expressing vaccine hesitancy: a registry-linkage study. Vaccine41, 1649â1656 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9889259</ArticleId><ArticleId IdType="pubmed">36746740</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles, R. et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults â increasing community access to testing program, United States, December 2022âJanuary 2023. Morb. Mortal. Wkly. Rep.72, 119â124 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9927070</ArticleId><ArticleId IdType="pubmed">36730051</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, S. S. et al. Forecasting daily patient volumes in the emergency department. Acad. Emerg. Med.15, 159â170 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18275446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya, R. P. &amp; Hanage, W. P. Challenges in inferring intrinsic severity of the SARS-CoV-2 Omicron variant. N. Engl. J. Med.386, e14 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35108465</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrotra, M. L. et al. CalScope: Monitoring severe acute respiratory syndrome coronavirus 2 seroprevalence from vaccination and prior infection in adults and children in California, May 2021âJuly 2021. Open Forum Infect. Dis.9, ofac246 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129171</ArticleId><ArticleId IdType="pubmed">35855959</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegand, R. E. et al. Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United StatesâOctober 25, 2020âFebruary 26, 2022. Lancet Reg. Health Am.18, 100403 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716971</ArticleId><ArticleId IdType="pubmed">36479424</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu, P. et al. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants. Cell187, 585â95.e6 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10872432</ArticleId><ArticleId IdType="pubmed">38194968</ArticleId></ArticleIdList></Reference><Reference><Citation>Roederer, A. L. et al. Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity. Preprint at medRxiv10.1101/2024.03.05.24303815v1 (2024).</Citation></Reference><Reference><Citation>Huiberts, A.J. et al. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024. Eurosurveillance29, 2400109 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10986669</ArticleId><ArticleId IdType="pubmed">38456217</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy, M. E. et al. XBB.1.5 mRNA COVID-19 vaccination and inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants. Preprint at medRxiv10.1101/2024.03.05.24303796v1 (2024).</Citation></Reference><Reference><Citation>Moustsen-Helms, I. R. et al. Realtive vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 Omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study. Lancet Infect. Dis.24, 964â973 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38761806</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi, K., Kahn, R., Boyer, C. &amp; Lipsitch, M. Some principles for using epidemiologic study results to parameterize transmission models. Preprint at medRxiv10.1101/2023.10.03.23296455 (2023).</Citation></Reference><Reference><Citation>Evans, S. J. W. &amp; Jewell, N. P. Vaccine effectiveness studies in the field. N. Engl. J. Med.385, 650â651 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314732</ArticleId><ArticleId IdType="pubmed">34289269</ArticleId></ArticleIdList></Reference><Reference><Citation>Honaker, J., King, G. &amp; Blackwell, M. Amelia II: a program for missing data. J. Stat. Softw.45, 7 (2011).</Citation></Reference><Reference><Citation>Schoenfeld, D. Partial residuals for the proportional hazards regression model. Biometrika69, 239â241 (1982).</Citation></Reference><Reference><Citation>Andrejko, K. L. et al. Receipt of COVDI-19 and seasonal influenza vaccines in California (USA) during the 2021-22 influenza season. Vaccine41, 1190â1197 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780637</ArticleId><ArticleId IdType="pubmed">36585281</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau, T. M. Package âsurvivalâ: survival analysis. Version 3.3-1. https://cran.r-project.org/web/packages/survival/survival.pdf (2024).</Citation></Reference><Reference><Citation>Lewnard, J. A. Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage, joelewnard/jn1, Release v1.0.0. 10.5281/zenodo.13712971 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11450198</ArticleId><ArticleId IdType="pubmed">39362845</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>